On this page
- Quick reference
- Dosage chart and four steps
- Supplies needed
- Peptide Reconstitution Simulator
- Vial and research context
- MOTS-C 10 mg Conversion Examples
- Human MOTS-C Dosage Evidence
- Storage Instructions
- How the MOTS-C Peptide Works: AMPK, Metabolic Health, and Insulin Sensitivity
- MOTS-C, Skeletal Muscle, Exercise, and Body Composition Research
- MOTS-C Research Evidence by Study Type
- MOTS-C Peptide Therapy Claims, Injection Safety, and Regulatory Limits
- Why MOTS-C Dose and Protocol Claims Conflict
- Potential Benefits of MOTS-C in Preclinical Research
- MOTS-C and Metformin: A Mechanistic Comparison, Not Equivalence
- MOTS-C Dosage Questions
- References
- Related research, protocols, and guides
MOTS-C Quick Reference (10 mg Vial)
- Vial contents
- 10 mg MOTS-C
- Final volume
- 3 mL
- Concentration
- 3.33 mg/mL
- One U-100 unit
- 33.33 mcg in 0.01 mL
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read MOTS-c Peptide: Benefits, Uses, Side Effects, Dosage, and Research.
MOTS-C Dosage Chart for a 10 mg Vial
Dosage and Reconstitution Chart
10 mg vial measurement guide for research calculations
Worked Measurement Sequence (3 mL = 3.33 mg/mL)
| Week | Amount per Administration | U-100 Units (Volume) |
|---|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) | 6 units (0.06 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 12 units (0.12 mL) |
| Weeks 5–6 | 600 mcg (0.6 mg) | 18 units (0.18 mL) |
| Weeks 7–8 | 800 mcg (0.8 mg) | 24 units (0.24 mL) |
| Weeks 9–10+ | 1,000 mcg (1.0 mg) | 30 units (0.30 mL) |
Illustrative frequency: The table uses once daily only to make the vial-use and supply calculations reproducible. It is not a recommended human schedule. Published human research measures endogenous MOTS-C rather than testing this injected sequence, and the FDA has not identified human exposure data for MOTS-C drug products.[3][4][15]
For the 6-unit row, a 30- or 50-unit U-100 syringe may make the marking easier to read. U-100 units are volume markings, not peptide international units.
Reconstitution Steps
- Draw 3.0 mL of bacteriostatic water with a sterile syringe.
- Inject the water slowly down the inside wall of the vial.
- Gently swirl or roll the vial until the powder dissolves. Do not shake.
- Label the vial with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Supplies Needed
Quantities below match the worked once-daily calculation sequence above. They do not establish a human research standard.
- Peptide Vials (MOTS-C, 10 mg each):
- 8 weeks: approximately 3 vials required
- 12 weeks: approximately 6 vials required
- 16 weeks: approximately 9 vials required
- Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL - 1 bottle required (10 mL each)
- 12 weeks (6 vials): 18 mL - 2 bottles required (10 mL each)
- 16 weeks (9 vials): 27 mL - 3 bottles required (10 mL each)
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs - 2 boxes required (100 swabs each)
- 12 weeks: 168 swabs - 2 boxes required (100 swabs each)
- 16 weeks: 224 swabs - 3 boxes required (100 swabs each)
Sharps safety: Place used syringes directly into an appropriate sharps container and follow local disposal requirements.[16]
Peptide Reconstitution Simulator
Practice preparing this vial with the verified strength and final volume from this protocol.
MOTS-C Vial and Research Context
- Vial contents: 10 mg MOTS-C.
- Final volume: 3.0 mL after reconstitution.
- Concentration: 3.33 mg/mL.
- U-100 conversion: 1 unit = 0.01 mL = about 33.3 mcg.
MOTS-C is a 16-amino-acid mitochondrial-derived peptide encoded within mitochondrial 12S rRNA. Laboratory studies connect it with metabolic stress signaling, AMPK activation, glucose regulation, and communication between mitochondria and the nucleus.[1][2] Human studies have measured naturally occurring MOTS-C in blood and its response to exercise, but those observational findings do not establish a dose, injection frequency, cycle, or treatment benefit for exogenous MOTS-C.[3][4]
MOTS-C 10 mg Conversion Examples
A 10 mg vial contains 10,000 mcg of MOTS-C. Adding 3.0 mL produces 3,333 mcg/mL. Because a U-100 syringe holds 100 units per mL, each unit contains about 33.3 mcg. These relationships are fixed mathematical conversions; they do not establish an appropriate MOTS-C dose for a person.
- 200 mcg: 0.06 mL, or 6 U-100 units.
- 400 mcg: 0.12 mL, or 12 units.
- 600 mcg: 0.18 mL, or 18 units.
- 800 mcg: 0.24 mL, or 24 units.
- 1,000 mcg: 0.30 mL, or 30 units.
Human MOTS-C Dosage Evidence
Current human research does not validate a MOTS-C injection dose. Studies have examined naturally circulating MOTS-C, associations with metabolic measures, and acute or chronic exercise responses.[4][6][7][8] Those designs cannot be converted into a subcutaneous dosage protocol. Searches of clinics, forums, and community discussions also reveal conflicting schedules rather than a reliable consensus, so those anecdotes were used only for private editorial context and are not cited as evidence.
Storage Instructions
Storage depends on the actual formulation and supplier documentation.
- Before reconstitution: Keep the sealed lyophilized vial dry, protected from light, and at the temperature specified on its label.
- After reconstitution: Refrigerate at 2–8 °C (35.6–46.4 °F) and protect from light.
- Discard date: Follow the formulation-specific label or laboratory stability documentation. A vial strength alone cannot establish a universal beyond-use period.
- Handling: Avoid vigorous shaking and unnecessary temperature cycling.
How the MOTS-C Peptide Works: AMPK, Metabolic Health, and Insulin Sensitivity
MOTS-C is translated from a short open reading frame within mitochondrial DNA and functions as a mitochondrial-derived signaling peptide. In cell and animal models, MOTS-C responds to metabolic stress and influences the folate and purine pathways, producing AICAR accumulation and AMPK activation.[1] AMPK is a cellular energy sensor that helps coordinate glucose uptake, lipid metabolism, and mitochondrial function when energy availability changes.
Laboratory work also shows that MOTS-C can move into the nucleus during metabolic stress and interact with adaptive stress-response transcriptional programs.[2] This mitochondria-to-nucleus communication is one reason MOTS-C research spans metabolic health, cellular energy, skeletal muscle, insulin sensitivity, aging, and longevity. These mechanisms are biologically interesting, but a molecular pathway is not proof that an exogenous MOTS-C injection produces a clinical benefit.
MOTS-C, Skeletal Muscle, Exercise, and Body Composition Research
Exercise research is frequently cited in discussions of MOTS-C dosage, but it answers a different question. Reynolds and colleagues reported that MOTS-C enhanced physical performance in mice and that exercise increased endogenous MOTS-C expression in human skeletal muscle and circulation.[3] A separate human study observed changes in circulating MOTS-C after acute endurance exercise.[4] Research in endurance-trained athletes has also examined associations between chronic training and plasma MOTS-C levels.[7]
These findings support MOTS-C as an exercise-responsive mitochondrial peptide, not as an exercise replacement or a validated peptide therapy. A blood-level response to exercise does not reveal how many milligrams of exogenous MOTS-C should be administered, how often it should be used, or whether a subcutaneous MOTS-C dosage is safe.
MOTS-C Research Evidence by Study Type
The strength of a MOTS-C claim depends on the study population and outcome. The research base includes several distinct layers:
- Cell and molecular studies: Establish proposed AMPK, nuclear-translocation, and metabolic-stress pathways.[1][2]
- Animal intervention studies: Report metabolic, exercise, ovarian, pancreatic-islet, immune, bone, cardiovascular, and skeletal-muscle findings in experimental models.[3][9][10][11][12][13][14]
- Human observational studies: Measure naturally occurring MOTS-C and examine associations with exercise or metabolic markers.[4][6][7][8]
- Human dosing evidence: The FDA’s 2026 technical review states that human exposure data for MOTS-C drug products were not identified.[15]
A 2023 review describes a broad experimental literature around metabolic homeostasis, stress, and aging, while a 2024 systematic review and meta-analysis summarizes human circulating MOTS-C findings.[5][6] Neither source establishes a standardized MOTS-C dosage protocol.
MOTS-C Peptide Therapy Claims, Injection Safety, and Regulatory Limits
Exogenous MOTS-C is investigational and is not FDA-approved. The FDA technical review identifies important uncertainties, including the absence of identified human exposure data, the potential for immunogenicity, and difficulty characterizing peptide-related impurities.[15] That means a reliable human side-effect rate, therapeutic window, maximum dose, interaction profile, and long-term safety record have not been established.
- Preclinical benefits cannot be assumed to occur in humans.
- Circulating MOTS-C levels are biomarkers, not dosing targets.
- Results for a modified analog cannot be transferred automatically to native MOTS-C.
- Purity, formulation, sterility, and storage can materially affect experimental risk.
- Community-reported reactions and schedules are inconsistent and do not substitute for controlled safety data.
Why MOTS-C Dose and Protocol Claims Conflict
Public descriptions of MOTS-C administration vary substantially. Some describe a daily protocol, while others describe one, two, or three times per week. Amounts per injection, cycle length, and timing also differ. That variation is evidence of uncertainty, not proof that several standardized MOTS-C protocols exist. No controlled human trial has established a standard protocol, a longevity protocol, or an optimal MOTS-C dose.
The worked sequence on this page is intentionally limited to vial concentration, units per injection, and supply math. It should not be used to infer that people treated with MOTS-C in clinical research received these amounts. Searches of anecdotal material also surfaced both favorable and negative reports, including reports of no noticeable effect, fatigue, skin reactions, and palpitations. Those accounts are not verified safety data and are not cited publicly, but they reinforce why community claims should not be converted into recommendations.
Potential Benefits of MOTS-C in Preclinical Research
The most frequently discussed metabolic benefits come from cell and animal experiments. In those models, MOTS-C improves aspects of glucose handling, insulin sensitivity, exercise performance, adipose homeostasis, and cellular energy regulation.[1][3][11] Other studies examine pancreatic-islet aging, autoimmune diabetes, bone metabolism, cardiovascular biology, and skeletal-muscle bioenergetics.[9][10][12][13][14]
These experiments help explain which metabolic pathways MOTS-C targets and why the peptide is being studied. They do not prove weight loss, improved body composition, better performance, or longevity in humans. Claims that MOTS-C helps achieve those outcomes remain unconfirmed until controlled human studies test exogenous MOTS-C directly.
MOTS-C and Metformin: A Mechanistic Comparison, Not Equivalence
MOTS-C and metformin are sometimes discussed together because both can intersect with AMPK-related metabolic signaling. The comparison is mechanistic only. It does not mean that MOTS-C acts like a clinically interchangeable medicine, produces the same effects, or has a known dose relationship with metformin. Metformin has extensive human clinical evidence; exogenous MOTS-C does not. The shared pathway should therefore be described as a research connection rather than a treatment comparison.
MOTS-C Dosage Questions
Is there an established human MOTS-C dosage?
No. Published human studies have measured endogenous MOTS-C, while the FDA reports that it has not identified human exposure data for MOTS-C drug products by any route.[4][15]
How much MOTS-C is in one U-100 unit after adding 3 mL?
A 10 mg vial diluted to 3.0 mL contains 3.33 mg/mL. One U-100 unit equals 0.01 mL, so one unit contains approximately 0.0333 mg, or 33.3 mcg.
Why does this MOTS-C dosage chart show 200 to 1,000 mcg?
Those rows provide a consistent worked example for translating peptide mass into U-100 syringe markings and for calculating supplies. They are not derived from a human trial and should not be described as a standard, recommended, or clinically validated MOTS-C dose.
Does a 10 mg vial change the underlying MOTS-C research?
No. Vial strength changes concentration, units per injection, total vial use, and supply math. It does not change the compound’s evidence base. The separate 5 mg, 20 mg, and 40 mg pages exist because their reconstitution and syringe conversions differ.
Does exercise research validate injected MOTS-C?
No. Exercise studies show that endogenous MOTS-C levels or expression can respond to physical activity.[3][4] They do not establish the safety or efficacy of exogenous MOTS-C administration.
References
- 1Cell Metabolism (2015) - The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee C, Zeng J, Drew BG, et al.)
- 2Cell Metabolism (2018) - The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress (Kim KH, Son JM, Benayoun BA, et al.)
- 3Nature Communications (2021) - MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds JC, Lai RW, Woodhead JST, et al.)
- 4Metabolites (2021) - Acute endurance exercise modulates circulating MOTS-c levels in humans
- 5Journal of Translational Medicine (2023) - Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging (Wan W, Zhang L, Lin Y, et al.)
- 6Systematic Review and Meta-analysis (2024) - Human circulating MOTS-c concentrations and metabolic health outcomes
- 7Human Exercise Study (2024) - Chronic endurance training and circulating MOTS-c levels in athletes
- 8Human Metabolic Study (2019) - Circulating MOTS-c in women with polycystic ovary syndrome and relationships with insulin and lipid measures
- 9Experimental & Molecular Medicine (2025) - Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Kong BS, Lee H, L’Yi S, et al.)
- 10Cell Reports Medicine (2021) - MOTS-c and immune-metabolic signaling in autoimmune diabetes models
- 11Journal of Molecular Medicine (2019) - MOTS-c regulates adipose homeostasis in an ovariectomy-induced metabolic dysfunction model
- 12Frontiers in Physiology (2023) - Role of MOTS-c in the regulation of bone metabolism
- 13Cardiovascular Research Review (2023) - Mitochondrial-derived peptides, including MOTS-c, in cardiovascular biology
- 14Skeletal Muscle Research (2026) - MOTS-c and muscle bioenergetics in a preclinical model
- 15U.S. Food and Drug Administration (2026) - Safety Risks Associated with Certain Bulk Drug Substances: MOTS-C technical review
- 16MedlinePlus Medical Encyclopedia - Subcutaneous injection and sharps-disposal guidance
Related research, protocols, and guides
Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.
Research overview
Other vial-strength protocols
Related protocols and comparisons